X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with TTK HEALTHCARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs TTK HEALTHCARE - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB TTK HEALTHCARE DR. REDDYS LAB/
TTK HEALTHCARE
 
P/E (TTM) x 35.4 33.7 105.2% View Chart
P/BV x 3.5 6.2 56.0% View Chart
Dividend Yield % 0.8 0.5 166.1%  

Financials

 DR. REDDYS LAB   TTK HEALTHCARE
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
TTK HEALTHCARE
Mar-14
DR. REDDYS LAB/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs3,397663 512.0%   
Low Rs2,560399 641.6%   
Sales per share (Unadj.) Rs856.5535.6 159.9%  
Earnings per share (Unadj.) Rs78.015.9 488.9%  
Cash flow per share (Unadj.) Rs139.920.0 698.6%  
Dividends per share (Unadj.) Rs20.004.00 500.0%  
Dividend yield (eoy) %0.70.8 89.2%  
Book value per share (Unadj.) Rs739.8137.6 537.6%  
Shares outstanding (eoy) m165.747.77 2,133.1%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.51.0 350.6%   
Avg P/E ratio x38.233.3 114.7%  
P/CF ratio (eoy) x21.326.5 80.3%  
Price / Book Value ratio x4.03.9 104.3%  
Dividend payout %25.725.1 102.3%   
Avg Mkt Cap Rs m493,6324,127 11,959.8%   
No. of employees `00022.71.7 1,327.9%   
Total wages/salary Rs m31,068607 5,121.7%   
Avg. sales/employee Rs Th6,259.02,436.7 256.9%   
Avg. wages/employee Rs Th1,369.8355.2 385.7%   
Avg. net profit/employee Rs Th569.772.5 785.3%   
INCOME DATA
Net Sales Rs m141,9614,162 3,411.0%  
Other income Rs m1,71561 2,802.3%   
Total revenues Rs m143,6764,223 3,402.2%   
Gross profit Rs m24,722197 12,542.9%  
Depreciation Rs m10,26632 32,384.9%   
Interest Rs m63430 2,120.4%   
Profit before tax Rs m15,537197 7,898.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,96573 4,072.8%   
Profit after tax Rs m12,921124 10,428.6%  
Gross profit margin %17.44.7 367.7%  
Effective tax rate %19.137.0 51.6%   
Net profit margin %9.13.0 305.7%  
BALANCE SHEET DATA
Current assets Rs m96,8371,629 5,945.7%   
Current liabilities Rs m84,1991,058 7,959.8%   
Net working cap to sales %8.913.7 64.9%  
Current ratio x1.21.5 74.7%  
Inventory Days Days7330 246.3%  
Debtors Days Days9834 290.8%  
Net fixed assets Rs m102,552556 18,434.7%   
Share capital Rs m82978 1,066.9%   
"Free" reserves Rs m121,792878 13,866.8%   
Net worth Rs m122,6211,069 11,467.4%   
Long term debt Rs m5,449159 3,433.5%   
Total assets Rs m218,1652,399 9,092.5%  
Interest coverage x25.57.6 336.6%   
Debt to equity ratio x00.1 29.9%  
Sales to assets ratio x0.71.7 37.5%   
Return on assets %6.26.4 96.9%  
Return on equity %10.511.6 90.9%  
Return on capital %12.918.5 69.9%  
Exports to sales %54.60.8 6,907.6%   
Imports to sales %9.41.4 667.5%   
Exports (fob) Rs m77,52033 235,623.1%   
Imports (cif) Rs m13,27458 22,768.4%   
Fx inflow Rs m81,67033 248,237.1%   
Fx outflow Rs m26,35563 41,707.5%   
Net fx Rs m55,315-30 -182,618.0%   
CASH FLOW
From Operations Rs m21,444127 16,938.4%  
From Investments Rs m-18,404-146 12,605.5%  
From Financial Activity Rs m-3,69222 -16,858.4%  
Net Cashflow Rs m-1,1443 -45,760.0%  

Share Holding

Indian Promoters % 25.5 65.4 39.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 3.7 145.9%  
FIIs % 35.3 5.2 678.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 25.8 59.3%  
Shareholders   75,885 12,723 596.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Idea Plunges 5% on Weak Q3 Peformance(Closing)

Indian share markets finished on a flat note after a five-session record-setting spree as profit booking was witnessed in metal stocks, capital goods stocks.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jan 24, 2018 03:33 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS